Fourth-year interim safety and patient outcomes from ESPRIT, a 10-year postmarketing surveillance registry of adalimumab for moderate to severe psoriasis

• Book ID: 122151974
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 53 KB
• Volume: 70
• Category: Article
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2014.01.707